Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL672840 | 0.98 | TSHR (0.58) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL7563889 | 0.98 | TSHR (0.58) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL673220 | 0.98 | TSHR (0.58) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL10427197 | 0.94 | TSHR (0.65) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL10427255 | 0.94 | TSHR (0.59) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL10426942 | 0.94 | TSHR (0.59) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL11647433 | 0.92 | TSHR (0.63) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL29940620 | 0.92 | TSHR (0.63) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL10150608 | 0.90 | TSHR (0.60) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL29763105 | 0.90 | TSHR (0.50) | TSHRALDH1A1TP53HIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195618-B2 | 3D printable resin compositions | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-01-14 | — | — | US | claimed |
| CN-118994654-A | Additive and polypropylene material and preparation method thereof | 国家能源集团宁夏煤业有限责任公司 | 2024-11-22 | — | — | CN | claimed |
| US-12015122-B2 | Silicon-based energy storage devices with carboxylic ether, carboxylic acid based salt, or acrylate electrolyte containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-06-18 | — | — | US | claimed |
| US-20230122021-A1 | 3D Printable Resin Compositions | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-04-20 | — | — | US | claimed |
| CN-111712523-B | Ophthalmic product composition | 爱尔兰眼力健公司 | 2023-01-03 | — | — | CN | claimed |
| EP-3728339-B1 | COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS | AMO Ireland (IE) | 2022-07-06 | — | — | EP | claimed |
| US-11359031-B2 | Composition for ophthalmological products | Johnson & Johnson Surgical Vision, Inc. (US) | 2022-06-14 | — | — | US | claimed |
| US-6194511-B1 | COMPRISING POLYMERIZABLE MONOMER CONTAINING SULFUR-CONTAINING (METH)ACRYLATE POLYMERIZABLE MONOMER AND PHOTOCHROMIC COMPOUND | TOKUYAMA CORPORATION (JP) | 2001-02-27 | — | — | US | claimed |
| US-20260140398-A1 | OPTICAL MATERIAL COMPOSITION, CURED BODY, OPTICAL ARTICLE, LENS, AND SPECTACLES | TOKUYAMA CORPORATION (JP) | 2026-05-21 | — | — | US | disclosed |
| EP-3901185-B1 | CURABLE COMPOSITION FOR OPTICAL MATERIALS, AND OPTICAL MATERIAL | TOKUYAMA CORP (JP) | 2026-03-25 | — | — | EP | disclosed |
| WO-2026044148-A1 | LOW GLOSS ELECTRON BEAM CURABLE COATING COMPOSITIONS | PPG INDUSTRIES OHIO, INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| EP-4696722-A1 | (METH)ACRYLATE, CURABLE COMPOSITION, CURED BODY, LAMINATE, OPTICAL ARTICLE, LENS, AND EYEGLASSES | TOKUYAMA CORPORATION (JP) | 2026-02-18 | — | — | EP | disclosed |
| US-12552745-B2 | Compound for optical materials, curable composition, cured body, and optical article | TOKUYAMA CORPORATION (JP) | 2026-02-17 | — | — | US | disclosed |
| EP-4644435-A1 | URETHANE (METH)ACRYLATE, CURABLE COMPOSITION, CURED BODY, LAMINATE, OPTICAL ARTICLE, LENSES, AND EYEGLASSES | TOKUYAMA CORPORATION (JP) | 2025-11-05 | — | — | EP | disclosed |
| EP-1427763-A1 | METHOD FOR THE PRODUCTION OF POLYMERS AND COPOLYMERS FROM ACRYLIC COMPOUNDS | Röhm GmbH & Co. KG (DE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003022897-A1 | METHOD FOR THE PRODUCTION OF POLYMERS AND COPOLYMERS FROM ACRYLIC COMPOUNDS | Röhm GmbH & Co. KG (DE) | 2003-03-20 | — | — | WO | disclosed |
| EP-0940694-B1 | Photochromic curable composition | TOKUYAMA CORP (JP) | 2002-08-14 | — | — | EP | disclosed |
| EP-1130038-A1 | CURABLE COMPOSITION | TOKUYAMA CORPORATION (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-6194511-B1 | COMPRISING POLYMERIZABLE MONOMER CONTAINING SULFUR-CONTAINING (METH)ACRYLATE POLYMERIZABLE MONOMER AND PHOTOCHROMIC COMPOUND | TOKUYAMA CORPORATION (JP) | 2001-02-27 | — | — | US | disclosed |
| EP-0940694-A1 | Photochromic curable composition | TOKUYAMA CORPORATION (JP) | 1999-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552745-B2 | Compound for optical materials, curable composition, cured body, and optical article | C5, SCO2, ZYX | TSHR 3533/4885ALDH1A1 1308/4885TP53 4357/4885 |
| US-20260140398-A1 | OPTICAL MATERIAL COMPOSITION, CURED BODY, OPTICAL ARTICLE, LENS, AND SPECTACLES | CRYAA, FEM1B, MAPRE1 | TSHR 4218/4885ALDH1A1 588/4885TP53 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.